Senti Biosciences to Present at H.C. Wainwright Global Investment Conference
PorAinvest
martes, 2 de septiembre de 2025, 9:11 am ET1 min de lectura
SNTI--
Dr. Lu will discuss Senti Biosciences' proprietary Gene Circuit platform and its clinical-stage cell and gene therapies. The Gene Circuit platform is designed to engineer new medicines with enhanced precision and control, capable of precisely killing cancer cells while sparing healthy cells and increasing specificity to target tissues. Senti Bio's pipeline includes cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. The platform has been shown preclinically to work in both NK and T cells and has demonstrated potential in other modalities and diseases outside of oncology.
In addition to the presentation, Senti Bio's management will be available for one-on-one meetings with qualified investors attending the conference. A live video webcast of the presentation will be available on Senti Bio's website, with a replay archived for 90 days following the event.
For more information about the conference, interested parties can visit the conference website. Additional information about Senti Bio can be found on the company's website, [Senti Bio](https://www.sentibio.com), or by following the company on X (@SentiBio) and LinkedIn (Senti Biosciences).
References:
[1] https://www.stocktitan.net/news/SNTI/senti-bio-to-present-at-the-h-c-wainwright-27th-annual-global-h01iszlz6505.html
[2] https://finance.yahoo.com/news/senti-bio-present-h-c-130500881.html
Senti Biosciences announced that Timothy Lu, CEO, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. Lu will discuss the company's Gene Circuit platform and its clinical-stage cell and gene therapies. The presentation will be available as a live webcast on Senti Bio's website, with a replay available for 90 days.
Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will take place on September 8, 2025, in New York, NY, with a presentation by Co-Founder and CEO Dr. Timothy Lu scheduled for 2:00 PM ET.Dr. Lu will discuss Senti Biosciences' proprietary Gene Circuit platform and its clinical-stage cell and gene therapies. The Gene Circuit platform is designed to engineer new medicines with enhanced precision and control, capable of precisely killing cancer cells while sparing healthy cells and increasing specificity to target tissues. Senti Bio's pipeline includes cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. The platform has been shown preclinically to work in both NK and T cells and has demonstrated potential in other modalities and diseases outside of oncology.
In addition to the presentation, Senti Bio's management will be available for one-on-one meetings with qualified investors attending the conference. A live video webcast of the presentation will be available on Senti Bio's website, with a replay archived for 90 days following the event.
For more information about the conference, interested parties can visit the conference website. Additional information about Senti Bio can be found on the company's website, [Senti Bio](https://www.sentibio.com), or by following the company on X (@SentiBio) and LinkedIn (Senti Biosciences).
References:
[1] https://www.stocktitan.net/news/SNTI/senti-bio-to-present-at-the-h-c-wainwright-27th-annual-global-h01iszlz6505.html
[2] https://finance.yahoo.com/news/senti-bio-present-h-c-130500881.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios